

**ANALISIS EFEKTIVITAS BIAYA TERAPI ANTIDIABETES
KOMBINASI METFORMIN DAN INSULIN DENGAN
METFORMIN DAN VILDAGLIPTIN PADA PASIEN T2DM DI
INSTALASI RAWAT JALAN RSUD BANDUNG KIWARI**

SKRIPSI

**RICE ASTARINA
A233022**



**SEKOLAH TINGGI FARMASI INDONESIA
YAYASAN HAZANAH
BANDUNG
2025**

**ANALISIS EFEKTIVITAS BIAYA TERAPI ANTIDIABETES
KOMBINASI METFORMIN+INSULIN DENGAN
METFORMIN+VILDAGLIPTIN PADA PASIEN T2DM DI
INSTALASI RAWAT JALAN RSUD BANDUNG KIWARI**

**RICE ASTARINA
A233022**

Juli 2025

Disetujui oleh :

Pembimbing



apt. M. Hilmi Fathurrahman, M.Farm

Pembimbing



apt. Nia Kurnia Sari, M.Si

Pembimbing



Falerina Puspita, S.Si., apt., M.Farm

Kutipan atau saduran baik sebagian ataupun seluruh naskah, harus menyebut nama pengarang dan sumber aslinya, yaitu Sekolah Tinggi Farmasi Indonesia.

ABSTRAK

Pembiayaan kesehatan di Indoensia semakin tinggi, maka diperlukan analisis efektivitas biaya untuk memilih obat yang efektif secara manfaat dan biaya. Tujuan penelitian untuk menganalisis efektivitas biaya dari dua kombinasi terapi yaitu metformin dan insulin dengan metformin dan vildagliptin pada pasien Diabetes Melitus Tipe 2 (T2DM) di RSUD Bandung Kiwari. Metodologi penelitian secara retrospektif terhadap data rekam medik. Data yang diperoleh diolah dan dianalisis menggunakan aplikasi SPSS dengan uji parametrik yaitu uji *independent t-test*. Efektivitas pengobatan diukur berdasarkan penurunan nilai HbA1c pasien terhadap nilai pemeriksaan awal. Hasil penelitian, efektivitas rata-rata terapi kombinasi metformin dan insulin adalah 2.02 %, metformin dan vildagliptin adalah 0.92 %. Rata-rata total biaya metformin dan insulin sebesar Rp 4.621.621,- metformin dan vildagliptin Rp 3.245.280,-. Perbandingan efektivitas penggunaan metformin dan insulin dengan metformin dan vildagliptin terhadap profil glikemik HbA1c yaitu 0,124 ($p > 0,05$), artinya tidak terdapat perbedaan signifikan terhadap profil glikemik pada kedua kelompok terapi. Analisis farmakoekonomi dengan metode *Cost Effectiveness Analysis* (CEA). Hasilnya, kelompok metformin dan insulin lebih *cost effective* dengan nilai ACER sebesar Rp 2.287.753,- dibandingkan dengan dengan metformin dan vildagliptin sebesar Rp 3.366.473,-. Perhitungan nilai ICER didapatkan sebesar Rp 1.298.095,-.

Kata Kunci: ACER, analisis farmakoekonomi, diabetes melitus, metformin insulin, metformin vildagliptin.

ABSTRACT

Healthcare costs in Indonesia are increasing, so it's important to analyze the cost-effectiveness of treatments to choose medicines that offer the best value in terms of benefits and cost. The purpose of this study was to analyze the cost-effectiveness of two treatment combinations—metformin and insulin, and metformin and vildagliptin—for patients with Type 2 Diabetes Mellitus (T2DM) at RSUD Bandung Kiwari. The research method used a retrospective analysis of medical records. The data was processed and analyzed using SPSS with a parametric test called the independent t-test. The effectiveness of the treatment was measured by the decrease in HbA1c levels compared to initial test results. The study found that the average effectiveness of the combination of metformin and insulin was 2.02%, while the combination of metformin and vildagliptin was 0.92%. The average total cost for metformin and insulin was Rp 4,621,621, while for metformin and vildagliptin it was Rp 3,245,280. The comparison of effectiveness between the two treatment groups in terms of HbA1c profiles showed a value of 0.124 ($p > 0.05$), which means there was no significant difference in glucose profiles between the two treatment groups. The pharmacoeconomic analysis used the Cost Effectiveness Analysis (CEA) method. The results showed that the group receiving metformin and insulin was more cost-effective, with an ACER value of Rp 2,287,753, compared to metformin and vildagliptin, which had an ACER value of Rp 3,366,473. The ICER calculation resulted in a value of Rp 1,298,095.

Keywords: ACER, pharmacoeconomic analysis, diabetes mellitus, metformin insulin, metformin vildagliptin.

KATA PENGANTAR

Bismillahirrahmanirrahim,

Puji dan syukur penulis panjatkan ke hadirat Allah SWT atas segala berkah rahmat dan ridho-Nya penulis dapat menyelesaikan penelitian dan penulisan skripsi yang berjudul “**Analisis Efektivitas Biaya Terapi Antidiabetes Kombinasi Metformin+Insulin dengan Metformin+Vildagliptin pada Pasien T2DM di Instalasi Rawat Jalan RSUD Bandung Kiwari**”.

Penelitian dan penulisan skripsi ini dilakukan untuk memenuhi salah satu syarat untuk mendapatkan gelar sarjana pada Program Studi Sarjana Farmasi Sekolah Tinggi Farmasi Indonesia.

Penulis mengucapkan terima kasih kepada dosen pembimbing, apt. Muhammad Hilmi Fathurrahman, M.Farm, apt. Nia Kurnia Sari, M.Si, Ibu Falerina Puspita, S.Si., Apt., M.Farm., atas bimbingan, nasihat, dukungan, serta saran dan masukan yang diberikan. Terima kasih telah dengan sabar, tekun, tulus dan ikhlas meluangkan waktu, tenaga dan pikiran memberikan bimbingan, motivasi, arahan, dan saran-saran yang sangat berharga kepada penulis selama menyusun skripsi. Pada kesempatan ini, tidak lupa penulis mengucapkan terima kasih yang sebesar-besarnya kepada semua pihak yang membantu penyusunan skripsi ini, yakni kepada:

1. Dr. apt. Adang Firmansyah, M.Si., selaku Ketua Sekolah Tinggi Farmasi Indonesia,
2. Dr. apt. Diki Prayugo, M.Si., selaku Wakil Ketua I Bidang Akademik,
3. Dr. apt. Hesti Riasari, M.Si., selaku Ketua Program Studi Sarjana Farmasi, dan selaku Dosen Wali yang telah banyak memberikan bimbingan dan arahan kepada penulis,
4. Seluruh staf dosen, staf administrasi, serta karyawan Sekolah Tinggi Farmasi Indonesia,
5. Kedua orangtua, suami dan anak-anakku sebagai penyemangat dan inspirasi dalam menjalani studi dan penelitian,
6. Serta teman-teman dekat yang telah bersama-sama berjuang, saling membantu dan mendukung selama penulis kuliah di Sekolah Tinggi Farmasi Indonesia.

Tak ada gading yang tak retak, demikian pula skripsi ini. Oleh karena itu, dengan kerendahan hati diharapkan masukan berupa kritik dan saran yang bersifat membangun untuk perbaikan di masa yang akan datang. Penulis berharap semoga tugas akhir ini akan memberikan manfaat bagi penulis sendiri dan juga bagi pihak lain yang berkepentingan.

Bandung, Juli 2025

Penulis

DAFTAR ISI

LEMBAR PENGESAHAN.....	i
KUTIPAN	ii
PERSEMBAHAN.....	ii
ABSTRAK	iv
<i>ABSTRACT</i>	v
KATA PENGANTAR.....	vi
DAFTAR ISI.....	vii
DAFTAR TABEL.....	ix
DAFTAR GAMBAR	x
DAFTAR LAMPIRAN	xi
BAB I PENDAHULUAN	1
1.1 Latar Belakang	1
1.2 Identifikasi Masalah.....	2
1.3 Tujuan Penelitian.....	2
1.4 Kegunaan Penelitian.....	2
1.5 Waktu dan Tempat Penelitian	3
BAB II TINJAUAN PUSTAKA	4
2.1 Diabetes Melitus.....	4
2.2 Anatomi Pankreas	4
2.3 Regulasi Kadar Glukosa Darah	7
2.4 Etiologi, Patofisiologi, Patogenesis.....	9
2.4.1 Patofisiologi Diabetes Melitus	9
2.4.2 Gejala Klinis.....	11
2.4.3 Faktor Risiko.....	13
2.5 Tujuan Terapi	14
2.6 Diagnosa	14
2.7 Penatalaksanaan Diabetes Melitus Tipe 2	15
2.8 Monitoring dan Evaluasi Terapi.....	24
2.9 Farmakoekonomi	24
2.9.1 Metode Analisis Farmakoekonomi	26
2.10 RSUD Bandung Kiwari	31
2.10.1 Definisi Rumah Sakit.....	31
2.10.2 Profil RSUD Bandung Kiwari	31

2.10.3 Pelayanan di RSUD Bandung Kiwari.....	31
BAB III TATA KERJA.....	33
3.1 Alat.....	33
3.2 Bahan	33
3.3 Metode Penelitian.....	33
3.3.1 Populasi dan Sampel.....	33
3.3.2 Penetapan Kriteria Sampel	34
3.3.3 Variabel Penelitian.....	34
3.3.4 Teknik Pengumpulan Data	35
3.3.5 Teknik Pengolahan Data.....	35
3.3.6 Teknik Analisis Data	35
3.3.7 Alur Penelitian	38
BAB IV HASIL DAN PEMBAHASAN	39
4.1 Alur Pengambilan Data.....	39
4.2 Karakteristik Pasien	41
4.2.1 Karakteristik Pasien Berdasarkan Jenis Kelamin.....	41
4.2.2 Karakteristik Pasien Berdasarkan Usia.....	42
4.2.3 Karakteristik Pasien Berdasarkan Diagnosis.....	43
4.3 Model Terapi Antidiabetes Kombinasi Pada Pasien T2DM.....	44
4.4 Efektivitas Terapi Antidiabetes Pada Pasien T2DM.....	45
4.5 Analisis Efektivitas Biaya.....	46
4.5.1 Biaya Medis Langsung	47
4.5.2 Perhitungan ACER Terapi Antidiabetes	48
4.5.3 Perhitungan ICER Terapi Antidiabetes	49
4.6 Analisis Sensitivitas	50
BAB V SIMPULAN DAN ALUR PENELITIAN SELANJUTNYA.....	53
5.1 Simpulan.....	53
5.2 Alur Penelitian Selanjutnya	53
DAFTAR PUSTAKA.....	54
LAMPIRAN.....	60

DAFTAR TABEL

Tabel	Halaman
2.1 Kadar tes laboratorium darah untuk diagnosis diabetes dan prediabetes...	15
2.2 Jenis dan Lama Kerja Insulin.....	22
2.3 Klasifikasi Biaya Dalam Farmakoekonomi	26
2.4 Metode analisis dalam kajian farmakoekonomi.....	27
2.5 Kelompok Alternatif berdasarkan Efektivitas-Biaya.....	30
3.1 Variabel Terikat.....	35
4.1 Karakteristik Pasien Berdasarkan Jenis Kelamin	41
4.2 Karakteristik Pasien Berdasarkan Usia.....	42
4.3 Karakteristik Pasien Berdasarkan Diagnosis	43
4.5 Hasil Pemeriksaan HbA1c Pada Kedua Kelompok Terapi.....	45
4.6 Rata-Rata Rincian Biaya Medik Langsung Terapi Antidiabetes dalam 1 tahun.....	47
4.7 Perhitungan ACER	48
4.8 <i>Cost-Effectiveness Grid</i>	49
4.9 Perhitungan ICER.....	49
4.10 Analisis Sensitivitas Biaya	51

DAFTAR GAMBAR

Gambar	Halaman
2.1 Anatomi Pankreas.....	5
2.2 Anatomi Pankreas (Makroskopik).....	6
2.3 Anatomi Pankreas (Mikroskopik).....	6
2.4 Kadar Glukosa Darah.....	8
2.5 Mekanisme Kerja Insulin.....	9
2.6 Patofisiologi Diabetes Melitus Tipe 2	11
2.7 <i>Ominous octec</i>	11
2.8 Algoritma tatalaksana DM tipe 2.....	18
2.9 Petunjuk Penggunaan Insulin.....	23
2.10 Algoritma Terapi Diabetes Mellitus Tipe 2	24
2.11 Diagram Efektivitas-Biaya.....	31
4.1 Alur Pengambilan Data	40
4.2 Analisis Sensitivitas Biaya Terapi Antidiabetes pada pasien T2DM di RSUB Bandung Kiwari	52

DAFTAR LAMPIRAN

Lampiran	Halaman
1 Permohonan Izin Penelitian dari Akademik.....	60
2 Surat Kode Etik.....	61
3 Surat Izin Penelitian dari Rumah Sakit Bandung Kiwari.....	62
4 Data Pasien Terapi Metformin+Insulin dan Penurunan HbA1c	63
5 Data Pasien Terapi Metfomin+Vildagliptin Dan Penurunan HbA1c	64
6 Data Biaya Medis Langsung Kelompok Terapi Metformin+Insulin	65
7 Data Biaya Medis Langsung Terapi Metformin + Vildagliptin	66
8 Output SPSS.....	67
9 Surat Keterangan Penelitian dari Kesbangpol	73

DAFTAR PUSTAKA

- Abdelhalim Yameny, A. and Yameny, A.A. (2024) 'Diabetes Mellitus Overview 2024', *Journal of Bioscience and Applied Research*, 10(3), pp. 641–645. Available at: <https://doi.org/10.21608/JBAAR.2024.382794>.
- Ahmed, A. *et al.* (2019) 'Molecular Basis of Blood Glucose Regulation', *Blood Glucose Levels*.
- Alam, M.R., Jyoti Talukdar, A. and Gogoi, B. (2023) 'Occurrence Of Dyslipidemia In Pre-Diabetic Individuals: A Hospital-Based Observational Study', *International Journal Of Scientific Research*, Pp. 64–66.
- Al-Mssallem, M.Q., Al-Qarni, A.A. and Al-Jamaan, M. (2020) 'Dietary carbohydrate intake in patients with type 2 diabetes mellitus and diabetes control: A cross-sectional study', *Food and Nutrition Research*, 64. Available at: <https://doi.org/10.29219/FNR.V64.4751>.
- Al-Suhaimi, E.A., Aljfary, M.A. and Khan, F.A. (2022) 'Endocrine Pancreas and Glucose Metabolism', *Emerging Concepts in Endocrine Structure and Functions*, pp. 247–285. Available at: https://doi.org/10.1007/978-981-16-9016-7_8.
- American Diabetes Association. (2020). Standards of Medical Care in Diabetes-2020. *Diabetes Care*, 43(Suppl 1), S1-S212.
- American Diabetes Association, 2023. 'The Relationship Between Diabetes and Hypertension: A Growing Epidemic', *Diabetes Care*, 46(5), pp. 789-798.
- Anshari, A.F., Ichsan, B. and Cholisoh, Z. (2023) 'Hubungan Kepatuhan Minum Obat terhadap HbA1C dan Kualitas Hidup Pasien Diabetes di RSI Purwodadi', *JPSCR: Journal of Pharmaceutical Science and Clinical Research*, 8(3), pp. 317–328. <https://doi.org/10.20961/JPSCR.V8I3.73753>.
- Armour, S.L. *et al.* (2023) 'Metabolic regulation of glucagon secretion', *Journal of Endocrinology*, 259(1). Available at: <https://doi.org/10.1530/JOE-23-0081>.
- Azeez, T.A. and Azeez, T.A. (2024) 'Present State and Perspectives of Type 2 Diabetes Management', *Type 2 Diabetes in 2024 - From Early Suspicion to Effective Management*. <https://doi.org/10.5772/INTECHOPEN.1002447>.
- Bollinger, L., *et al.*, 2022. *Sleep Disorders and Their Impact on Metabolism: A Link to Type 2 Diabetes*. *Sleep Medicine Reviews*, 56, pp. 25-34.
- Biostatistik, J. *et al.* (2021) 'Part of the Health Information Technology Commons, and the Health Services Research Commons Recommended Citation Recommended Citation Lubis', *Rifa Fadhillah and Kanzasabilla*, 1(3), p. 4. Available at: <https://doi.org/10.7454/bikfokes.v1i3.1016>.
- Chadha, M. *et al.* (2023) 'Evolution of Guideline Recommendations on Insulin Therapy in Type 2 Diabetes Mellitus Over the Last Two Decades: A Narrative Review', *Current Diabetes Reviews*, 19(8). Available at: <https://doi.org/10.2174/1573399819666230116150205>.
- Chadt, A. and Al-Hasani, H. (2020) 'Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease', *Pflugers Archiv European Journal of Physiology*, 472(9), pp. 1273–1298. Available at: <https://doi.org/10.1007/S00424-020-02417-X>.

- Chaudhari, Y.S. *et al.* (2023) 'Diabetes Mellitus: A Review', *International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)*, 3(1). <https://doi.org/10.48175/IJARSCT-8551>.
- 'Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020' (2020) *Diabetes Care*, 43(Suppl 1), pp. S14–S31. Available at: <https://doi.org/10.2337/DC20-S002>.
- Collein, I. (2023) 'The Effect of 4 Pillars of Health Education on Blood Sugar Levels in Type 2 Diabetes Mellitus', *Poltekita: Jurnal Ilmu Kesehatan*, 17(3), pp. 529–534. <https://doi.org/10.33860/JIK.V17I3.2290>.
- Jain, R. *et al.* (2023) 'Gender-Based Comparative Study of Type 2 Diabetes Risk Factors in Kolkata, India: A Machine Learning Approach'.
- Zhang, H. *et al.* (2019) 'Sex-based differences in diabetes prevalence and risk factors: A population-based cross-sectional study among low-income adults in China', *Frontiers in Endocrinology*, 10(SEP), p. 425183.
- Dunkley, A., *et al.*, 2022. *Age as a Risk Factor for Type 2 Diabetes: A Review of Evidence*. *Journal of Aging and Health*, 32(3), pp. 412-425.
- Durán, A., Orozco, M., & Martínez, A. (2019). Comparative effectiveness of DPP-4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis. *Diabetes Research and Clinical Practice*, 153, 198-205.
- Drummond, M., Sculpher, M., Claxton, K., Stoddart, G. & Torrance, G. (2015). *Methods for the Economic Evaluation of Health Care Programmes*. 4th ed. Oxford: Oxford University Press.
- Hamer, M., *et al.*, 2022. *The Effects of Smoking and Alcohol Consumption on Type 2 Diabetes Risk*. *Diabetes Care*, 45(8), pp. 1435-1440.
- Desianti, S. *et al.* (2018) 'Review Artikel: Kajian Farmakoekonomi Yang Mendasari Pemilihan Pengobatan Di Indonesia', *Farmaka*, 16(3). Available at: <https://doi.org/10.24198/JF.V16I3.17435>.
- Endokrinologi Indonesia Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia-2021 Perkeni Penerbit Pb. Perkeni'.
- Flores-López, L.A. *et al.* (2024) 'Pancreatic β cell apoptosis in type 2 diabetes is related to post translational modifications of p53 (Review)', *Molecular Medicine Reports*, 30(5). <https://doi.org/10.3892/MMR.2024.13317>.
- Hadning, I. *et al.* (2024) 'Cost effectiveness analysis of antihypertensive captopril and amlodipine in patients with primary hipertension', *AIP Conference Proceedings*, 3155(1). <https://doi.org/10.1063/5.0218035/3297839>.
- Hardianto, D. (2020) 'TELAHAH KOMPREHENSIF DIABETES MELITUS: KLASIFIKASI, GEJALA, DIAGNOSIS, PENCEGAHAN, DAN PENGOBATAN', *Jurnal Bioteknologi dan Biosains Indonesia*, 7(2), pp. 304–317. Available at: <https://doi.org/10.29122/jbbi.v7i2.4209>.
- Hajam, Y.A. *et al.* (2022) 'Diabetes Mellitus: Signs and Symptoms, Epidemiology, Current Prevention, Management Therapies, and Treatments', *Antidiabetic Potential of Plants in the Era of Omics*, pp. 31–77. Available at: <https://doi.org/10.1201/9781003282860-3>.
- Hamer, M., *et al.*, 2022. *The Effects of Smoking and Alcohol Consumption on Type 2 Diabetes Risk*. *Diabetes Care*, 45(8), pp. 1435-1440.
- HAZARI, ANIMESH. (2024) 'Research Methodology For Allied Health Professionals : a comprehensive guide to thesis ... & dissertation', p. 134.

- Herold, K.C. and Krischer, J.P. (2024) 'The Pathogenesis of Type 1 Diabetes', Cold Spring Harbor perspectives in medicine, p. a041623. Available at: <https://doi.org/10.1101/CSHPERSPECT.A041623>.
- Hossain, T. *et al.* (2024) 'Role of physical activity for glycemic control among patients with type 2 diabetes mellitus', *BIRDEM Medical Journal*, 14(3), pp. 143–150. Available at: <https://doi.org/10.3329/BIRDEM.V14I3.76239>.
- IDF Diabetes Atlas 2025 | Global Diabetes Data & Insights (no date). Available at: <https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/> (Accessed: 19 July 2025).
- Jiang, Y., *et al.*, 2023. *Environmental and Socioeconomic Factors in Type 2 Diabetes Prevalence*. *International Journal of Environmental Research and Public Health*, 20(4), pp. 895-906.
- Jadon, A.S. *et al.* (2024) 'Types of diabetes mellitus, mechanism of insulin resistance and associated complications', *Biochemical Immunology of Diabetes and Associated Complications*, pp. 1–18. Available at: <https://doi.org/10.1016/B978-0-443-13195-0.00001-6>.
- Juan, J. *et al.* (2022) 'Prevalence and characteristics of macrosomia in the first and subsequent pregnancy: a multi-center retrospective study', *Chinese Medical Journal*, 135(12), p. 1492. Available at: <https://doi.org/10.1097/CM9.0000000000002077>.
- Jung, I., Koo, D.J. and Lee, W.Y. (2024) 'Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective', *Diabetes & Metabolism Journal*, 48(3), pp. 327–339. Available at: <https://doi.org/10.4093/DMJ.2023.0350>.
- Koh, E., *et al.*, 2023. *Stress and Mental Health in Diabetes Management: A Comprehensive Review*. *Diabetes Research and Clinical Practice*, 171, pp. 108-115.
- Kato, Y., Zong, Y. and Lee, S.H., 2022. 'Long-Term Impact of Diabetic Nephropathy on Hypertension and Cardiovascular Events', *Journal of Diabetes Research*, 2022(8), pp. 23-34.
- Kemenkes RI (2013) 'Buku Pedoman Farmakoekonomi Kajian Farmakoekonomi'. Kesavadev, J. *et al.* (2019) 'Pathophysiology of Type 2 Diabetes', *The Diabetes Textbook*, pp. 101–116. Available at: https://doi.org/10.1007/978-3-030-11815-0_8.
- Kristin, E. (2017) 'Kristin, Combination treatment for type 2 diabetes mellitus (T2DM): dipeptidyl peptidase-4 inhibitors (DPP-4) and metformin Combination treatment for type 2 diabetes mellitus (T2DM): dipeptidyl peptidase-4 inhibitors (DPP-4) and metformin', *J Med Sci*, 49(3), pp. 141–151. Available at: <https://doi.org/10.19106/JMedSci00403201701>.
- Li, R., *et al.*, 2023. *Genetic Predisposition to Type 2 Diabetes and Implications for Prevention*. *Diabetes Care*, 46(2), pp. 213-220.
- LAPORAN SKI 2023 DALAM ANGKA_REVISI I_OK.pdf - Google Drive (no date). Available at: https://drive.google.com/file/d/1rjNDG_f8xG6-Y9wmhJUnXhJ-vUFevVJC/view (Accessed: 7 July 2025).
- Lewis, B. and Mao, J. (2023) 'Development of the Pancreas and Related Structures', *The Pancreas: an Integrated Textbook of Basic Science, Medicine, and Surgery*, Fourth Edition, pp. 3–8. Available at: <https://doi.org/10.1002/9781119876007.CH1;CTYPE:STRING:BOOK>.

- Longnecker, D.S. (2021) 'Anatomy and Histology of the Pancreas', Pancreapedia: The Exocrine Pancreas Knowledge Base [Preprint]. Available at: <https://doi.org/10.3998/PANC.2021.01>.
- Lu, X. *et al.* (2024) 'Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy', *Signal Transduction and Targeted Therapy*, 9(1). Available at: <https://doi.org/10.1038/S41392-024-01951-9>.
- Mohajan, D. and Mohajan, H.K. (2023a) 'Basic Concepts of Diabetics Mellitus for the Welfare of General Patients', *Studies in Social Science & Humanities*, 2(6), pp. 23–31. <https://doi.org/10.56397/SSSH.2023.06.03>.
- Mohajan, D. and Mohajan, H.K. (2023b) 'Basic Concepts of Diabetics Mellitus for the Welfare of General Patients', *Studies in Social Science & Humanities*, 2(6), pp. 23–31. <https://doi.org/10.56397/SSSH.2023.06.03>.
- Mauskopf, J., Gray, A., & Green, L. (2019). 'The Application of Cost-Effectiveness Analysis to Health Interventions', *Pharmacoeconomics*, 37(3), pp. 405–416.
- Ningsih, P.K. and Subagijo, P.B. (2017) 'Analisis Efektivitas Biaya Penggunaan Antibiotik terhadap Pasien Sepsis di RSD dr. Soebandi Tahun Analisis Efektivitas Biaya Penggunaan 2014-2015 (Cost Effectiveness Analysis of Antibiotic Used for Sepsis Patients in dr. Soebandi Hospital During 2014-2015)', *Pustaka Kesehatan*, 5(1), pp. 151–156. Available at: <https://doi.org/10.19184/PK.V5I1.5385>.
- Robinson, P., Walker, D., & Smith, J. (2021). Insulin therapy in type 2 diabetes: balancing efficacy and safety. *Diabetes, Obesity and Metabolism*, 23(4), 785–794.
- Siegler, A., *et al.*, 2022. *Dietary Patterns and the Risk of Type 2 Diabetes: A Systematic Review*. *American Journal of Clinical Nutrition*, 116(6), pp. 1256–1265.
- Smith, T., James, K., & Clark, L. (2021). Insulin resistance in type 2 diabetes and its management. *The Journal of Clinical Endocrinology & Metabolism*, 106(2), 512–520.
- Odegard, P.S., Winter, A. and Capoccia, K.L. (2024) 'Biguanides', 2024-25 Guide to Medications for the Treatment of Diabetes Mellitus, pp. 114–143. Available at: <https://doi.org/10.2337/9781580408387.CH06>.
- Open Data Jabar. https://opendata.jabarprov.go.id/id?id?utm_source (Accessed: 7 July 2025).
- Pangestuningsih, M. and Rukminingsih, F. (no date) 'Gambaran Fungsi Hati Pasien Diabetes Melitus Tipe II Di Salah Satu Rumah Sakit Swasta Di Kabupaten Demak Periode Oktober-Desember 2020', 4(2), p. 2022.
- Papanastasiou, A. *et al.* (2024) 'ARTERIAL HYPERTENSION AND INSULIN RESISTANCE IN OBESE PATIENTS', *Journal of Hypertension*, 42(Suppl 1), p. e142. <https://doi.org/10.1097/01.HJH.0001020776.94064.F2>.
- Probosari, E. (2020) 'Penatalaksanaan Gizi pada Pasien dengan Kanker Pankreas', *JNH (Journal of Nutrition and Health)*, 6(1), pp. 21–30. Available at: <https://doi.org/10.14710/JIS>.
- Prodyanasari, A. *et al.* (2024) 'Editor: Arshy Prodyanasari, M.Pd'.
- Rahman, M.S. *et al.* (2021) 'Role of Insulin in Health and Disease: An Update', *International Journal of Molecular Sciences*, 22(12), p. 6403. Available at: <https://doi.org/10.3390/IJMS22126403>.
- Salazar, B.D.A., Ortega, F.R.G. and Kalschne, I.D.C. (2024) 'COMPLICAÇÕES

- CRÔNICAS DO DIABETES MELLITUS TIPO 2', *Revista ft*, pp. 05–06. Available at: <https://doi.org/10.69849/REVISTAFT/NI10202410280705>.
- Sana, A. *et al.* (2024) 'A CROSS-SECTIONAL STUDY TO INVESTIGATE COST-RELATED NON-ADHERENCE AMONG DIABETIC PATIENTS IN TWIN CITIES', *Insights-Journal of Health and Rehabilitation*, 2(2 (Health & Allied)), pp. 434–442. <https://doi.org/10.71000/IJHR141>.
- Sari, N.A. *et al.* (2024) 'ANALISIS PENGARUH REBUSAN DAUN KELOR UNTUK MENURUNKAN KADAR GULA DARAH PENDERITA DIABETES MELLITUS TIPE 2', *Jurnal Cahaya Mandalika* ISSN 2721-4796 (online), 5(2), pp. 741–746. <https://doi.org/10.36312/JCM.V5I2.2273>.
- Scanlon, V.C.. and Sanders, Tina. (2019) 'Essentials of anatomy and physiology', p.608.https://books.google.com/books/about/Essentials_of_Anatomy_and_Physiology.html?hl=id&id=oXAotAEACAAJ (Accessed: 7 July 2025).
- Scapin, G. *et al.* (2018) 'Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis', *Nature*, 556(7699), pp. 122–125. Available at: <https://doi.org/10.1038/NATURE26153>,.
- Soelistijo, S.A. *et al.* (2015) 'Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015', *Perkeni*, p. 78. Available at: <https://doi.org/10.1017/CBO9781107415324.004>.
- Torrance, G.W. (2020). 'The Measurement of Quality of Life in Health Care', *Pharmacoeconomics*, 38(5), pp. 469–478.
- Tabitha, R., Syarif, S. and Wahyono, T.Y.M. (2024) 'Factors Related to the Incidence of Diabetes Mellitus in the Kebon Baru Primary Health Center in South Jakarta in 2020', *Media Publikasi Promosi Kesehatan Indonesia (MPPKI)*, 7(7), pp. 1884–1895 <https://doi.org/10.56338/MPPKI.V7I7.5444>.
- Timur, W.W., Asmahan, D. and Pradesti, N. (2024) 'Perbedaan Efektivitas Penggunaan Metformin-Insulin versus Metformin-Vildagliptin Terhadap Profil Glikemik Pasien DMT2 di Instalasi Rawat Jalan RSISA Periode 2022', *JPSCR: Journal of Pharmaceutical Science and Clinical Research*, 9(1), pp. 1–10. Available at: <https://doi.org/10.20961/JPSCR.V9I1.71945>.
- Ulfa, N.M., Fandinata, S.S. and Puspitasari, I. (2023) 'Analisis Efektifitas Biaya Terapi Pengobatan Pasien Diabetes Mellitus Tipe 2 terhadap Kontrol Glukosa Darah', *Jurnal Kefarmasian Indonesia*, pp. 83–94. Available at: <https://doi.org/10.22435/JKI.V13I1.6170>.
- V. Ramani, T., Pratyusha, M. and Saritha, S. (2020) 'Chronological study in microanatomy of human foetal pancreatic tissue', *Indian Journal of Clinical Anatomy and Physiology*, 5(4), pp. 559–563. <https://doi.org/10.18231/2394-2126.2018.0126>.
- Vreman, R.A. *et al.* (2021) 'The Application and Implications of Novel Deterministic Sensitivity Analysis Methods', *Pharmacoeconomics*, 39(1), pp. 1–17. Available at: <https://doi.org/10.1007/S40273-020-00979-3>.
- Winther, J.B. and Holst, J.J. (2024) 'Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity', *Diabetes, Obesity and Metabolism*, 26(9), pp. 3501–3512. Available at: <https://doi.org/10.1111/DOM.15693>.
- Wulandari, I. *et al.* (2021) 'Family support in caring for diabetes mellitus patient: Patient's perspective', *Open Access Macedonian Journal of Medical Sciences*, 9(T4), pp. 199–205. Available at:

- <https://doi.org/10.3889/OAMJMS.2021.5778>.
- World Health Organization (WHO), 2023. *Obesity and Diabetes: A Growing Epidemic*.
- Yu, Q. *et al.* (2019) 'Glucose controls glucagon secretion by directly modulating cAMP in alpha cells', *Diabetologia*, 62(7), pp. 1212–1224. Available at: <https://doi.org/10.1007/S00125-019-4857-6>.
- Zhang, X., *et al.*, 2023. *Obesity and Type 2 Diabetes: A Complex Relationship*. *Journal of Obesity*, 45(4), pp. 234-240.
- Zhang, H. *et al.* (2019) 'Sex-based differences in diabetes prevalence and risk factors: A population-based cross-sectional study among low-income adults in China', *Frontiers in Endocrinology*, 10(SEP), p. 425183.
- Zhao, J. *et al.* (2020) 'Anti-Lipolysis Induced by Insulin in Diverse Pathophysiologic Conditions of Adipose Tissue', *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 13, p. 1575. Available at: <https://doi.org/10.2147/DMSO.S250699>.
- Zong, Y., Lee, S.H., and Piero, P., 2023. 'Metabolic Syndrome and Cardiovascular Risk in Type 2 Diabetes: A Study of the Interplay', *Journal of Clinical Endocrinology and Metabolism*, 38(4), pp. 459-467.